Key result
SGLT2 inhibitors linked to ~2-fold higher DKA risk compared to DPP-4 inhibitors.
Key points are not available for this paper at this time.
A study that assessed the risk of diabetic ketoacidosis after the initiation of SGLT2 inhibitor therapy showed nearly twice the risk as with a DPP4 inhibitor.
No takes yet. Share an insight, caveat, or question.
Fralick et al. (2017) studied this question. SGLT2 inhibitors were associated with nearly twice the risk of diabetic ketoacidosis compared to DPP4 inhibitors.
Synapse has enriched 5 related papers. Consider them for comparative context: